---
title: Pulmonaryhypertension in Copd at Different Levels of Smoking
nct_id: NCT06031311
overall_status: UNKNOWN
sponsor: Assiut University
study_type: OBSERVATIONAL
primary_condition: Pulmonary Hypertension
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06031311.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06031311"
ct_last_update_post_date: 2023-09-14
last_seen_at: "2026-05-12T06:33:48.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Pulmonaryhypertension in Copd at Different Levels of Smoking

**Official Title:** Clinical Characteristics and Predictors of Pulmonary Hypertension in COPD at Different Levels of Smoking

**NCT ID:** [NCT06031311](https://clinicaltrials.gov/study/NCT06031311)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 138
- **Lead Sponsor:** Assiut University
- **Conditions:** Pulmonary Hypertension
- **Start Date:** 2023-10-01
- **Completion Date:** 2024-12-01
- **CT.gov Last Update:** 2023-09-14

## Brief Summary

To identify Predictors of pulmonary hypertension in COPD patients and its relation to different levels of smoking

## Detailed Description

COPD is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.It is also the most common cause of deaths in patients with chronic respiratory disease, the fatality rate in USA is 0.41%.Pulmonary Hypertension is the most common serious complication in COPD patients ; which occurs in up to 30% of patients and increases the mortality rate.Smoking is the leading cause of chronic obstructive pulmonary disease (COPD) Smoking is also a trigger for COPD flare-ups.Smoking damages the air sacs, airways, and the lining of your lungs. Injured lungs have trouble moving enough air in and out, so it's hard to breathe

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 100 Years
- **Sex:** ALL

```
Inclusion Criteria:

* 1.All patients admitted to chest department or presented to our outpatient clinic with clinical and functional diagnosis of COPD among both sexes will be included 2.Age \>18 years Old

Exclusion Criteria:

* 1.Patients under 18 years old. 2.pregnant patients. 3.patients with history hypertension or valvular diseases 4.Cardiomyopathic patient 5.Patients with concomitant obstructive sleep apnea 6.Patients with collagen vascular disease 7.Patients with thrombo-embolic disease 8. Patients with any chronic chest disease other than COPD
```

## Interventions

- **Echocardiography and HRCT** (DIAGNOSTIC_TEST) — Echocardiography:is non invasive and easily accessible tool in the diagnosis of any patient with suspected PH.HRCT: is a non-invasive and easily accessible tool to detect pulmonary hypertension in COPD patients.

## Primary Outcomes

- **Predictors of pulmonary hypertension in COPD patients** _(time frame: 1 year)_ — Predict pulmonary hypertension in COPD patients

## Secondary Outcomes

- **Relationship between different levels of smoking and predictors of degree of pulmonary hypertension** _(time frame: 1 year)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06031311.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06031311*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*